These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 32464483)
21. [Intra and extra hepatic cholangiocarcinomas radiation therapy]. Moreau J; Lapeyre M; Benoit C; Pezet D; Biau J Cancer Radiother; 2021 Apr; 25(2):175-181. PubMed ID: 33423966 [TBL] [Abstract][Full Text] [Related]
22. Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer. Wardley A Oncologist; 2006; 11 Suppl 1():20-6. PubMed ID: 16971736 [TBL] [Abstract][Full Text] [Related]
23. Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time. Messori A; Bartoli L; Trippoli S Dig Liver Dis; 2020 Oct; 52(10):1208-1209. PubMed ID: 32505564 [No Abstract] [Full Text] [Related]
24. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers. Kish M; Chan K; Perry K; Ko YJ Curr Oncol; 2020 Feb; 27(1):e20-e26. PubMed ID: 32218664 [TBL] [Abstract][Full Text] [Related]
25. [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies]. Créhange G; Bosset JF; Maingon P Cancer Radiother; 2011 Oct; 15(6-7):440-4. PubMed ID: 21802334 [TBL] [Abstract][Full Text] [Related]
26. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186 [No Abstract] [Full Text] [Related]
33. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Kim YS; Jeong CY; Song HN; Kim TH; Kim HJ; Lee YJ; Hong SC Chin J Cancer; 2017 Jan; 36(1):9. PubMed ID: 28086990 [TBL] [Abstract][Full Text] [Related]
34. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411 [TBL] [Abstract][Full Text] [Related]
35. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606 [TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429 [TBL] [Abstract][Full Text] [Related]
37. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis. Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875 [TBL] [Abstract][Full Text] [Related]
38. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Ajani J Cancer; 2006 Jul; 107(2):221-31. PubMed ID: 16770784 [TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J; Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845 [TBL] [Abstract][Full Text] [Related]